Partner Headlines - AMGN

  1. The Other Bearish Biotech ETF Is Looking Groovy, Too

    Benzinga
  2. These 6 Stocks Skyrocketed During The 2008 Crash

    Benzinga
  3. Dan Loeb Is Still Bullish On Amgen, Allergan and Dow Chemical

    Benzinga
  4. The Best Companies of the Pharmaceuticals Industry - August 2 ...

    GuruFocus
  5. What Are Payors Saying About Managed Care Giants?

    Benzinga
  6. The Historical Correlation Between Biotech Stocks And Interest ...

    Benzinga
  7. These Two Biotechs Boast Big EPS Growth Rates

    IBD
  8. Allergan Q2 Beats, But Generics Sale Clouds Outlook

    IBD
  9. What Company Will Be Fastest Growing Big-Cap Biotech?

    IBD
  10. Social Media Beat: What The Crowd & Experts Think Of Oil, Biotech ...

    Benzinga
  11. Amgen Stock Hits High As Street Eyes Growth Drivers

    IBD
  12. Stocks Open Mixed, Dow Lags; Expedia, Amgen, NewLink Rising

    IBD
  13. Stock Futures Reverse Higher; Skywest, LinkedIn, Expedia In Motion

    IBD
  14. Fast Money Picks For July 31

    Benzinga
  15. 7 Must Watch Stocks for Today

    Benzinga
  16. Amgen, Alexion Q2 Earnings Beat, But Guidance Differs

    IBD
  17. Amgen, Alexion Profits Beat

    IBD
  18. Stocks Finished Mixed; LinkedIn Leaps, Then Gives It Back

    IBD
  19. Thursday's After-Hours Movers: Earnings Shaking LinkedIn, Expedia, ...

    Benzinga
  20. Amgen Posts Upbeat Q2 Results, Lifts 2015 Guidance

    Benzinga
  21. Stocks Stay Mixed; Cavium Reverses Higher

    IBD
  22. Even With Recent Declines, Investors Still Love Biotech ETFs

    Benzinga
  23. Gilead Gets Wall Street Love After Q2 Earnings Beat

    IBD
  24. Amgen Stock Clears Buy Point Ahead Of Earnings

    IBD
  25. Is More M&A On The Way For Large-Cap Biotechs?

    Benzinga
  26. Biotech NantKwest Stock Surges On 1st Day Of Trading

    IBD
  27. Benzinga's M&A Chatter for Monday July 27, 2015

    Benzinga
  28. A Big Day For Biotech And It's Not Going So Well

    Benzinga
  29. Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK

    IBD
  30. US Stock Futures Mixed; All Eyes On Apple, Microsoft Earnings

    Benzinga
  31. Why Big Biotech Could Have Another Leg Up

    Benzinga
  32. Perrigo Company Is Strong But Overvalued

    GuruFocus
  33. Regeneron, Amgen Downgraded As Biotech Seen Slowing

    IBD
  34. Benzinga's Top Downgrades

    Benzinga
  35. Large-Cap Biotechs Poised For Second-Half Rally, RBC Says

    Benzinga
  36. Benzinga's Top #PreMarket Losers

    Benzinga
  37. UBS Downgrades Amgen On 'Waiting Game,' Removes Brodalumab From ...

    Benzinga
  38. US Stock Futures Jump Ahead Of Jobless Claims Data

    Benzinga
  39. What Is Beyond Vision-Loss Blockbuster For Regeneron?

    IBD
  40. Amgen Among 3 Medical Giants With Healthy Payouts

    IBD
  41. Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's ...

    Benzinga
  42. Biotech Short-Sellers Prefer Amgen To Gilead Sciences

    Benzinga
  43. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  44. ProShares Releases 2 New Leveraged Biotech ETFs

    Benzinga
  45. An Ebola-Fighting Portfolio For The Present...And The Future

    Benzinga
  46. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  47. Biotech ETFs Hit New 2015 Highs

    Benzinga
  48. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  49. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus
  50. Why Drugmaker AbbVie Can Power Past Patent Expiration

    IBD
  51. New Migraine Drugs Could Ease Investors' Headaches

    IBD
  52. FDA Cautious On New Drugs

    IBD
  53. Amgen Cholesterol Drug Repatha Wins FDA Panel Vote

    IBD
  54. Regeneron, Amgen Fall On Cholesterol Drug Worries

    IBD
  55. FDA Panel Backs Regeneron

    IBD
  56. Regeneron/Sanofi Cholesterol Drug Wins FDA Panel Vote

    IBD
  57. FDA Looking at New Drugs to Lower "Bad" Cholesterol

    FoxBusiness
  58. FDA weighs cholesterol fighter

    IBD
  59. Are 4 Top-Rated IBD 50 Drug Stocks On Your Radar?

    IBD
  60. FDA: Cholesterol Drug Works

    IBD
  61. Regeneron/Sanofi Cholesterol Drug Under FDA Scrutiny

    IBD
  62. PRIMECAP Sells Portions of Its Top Two Stakes

    GuruFocus
  63. Amgen And AstraZeneca's Deal On Psoriasis Drug Faces Termination

    GuruFocus
  64. 5 Drugs That Could Be Summer Blockbusters

    IBD
  65. CNBC's Stock Pops & Drops From May 26

    Benzinga
  66. Amgen's Cholesterol Fighting Drug Receives EU Approval

    GuruFocus
  67. Amgen Down After Suicides Kill AstraZeneca Deal

    IBD
  68. Morgan Stanley Found This 'Unexpected Negative' At Amgen

    Benzinga
  69. 5 Drugs That Could Be Summer Blockbusters

    IBD
  70. Amgen gets cholesterol edge

    IBD
  71. Health Care Sector Delivers Healthy Q1 Results

    IBD
  72. IPO Stock Watch: Alder Soars On Migraine Drug Results

    IBD
  73. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  74. The Best And Worst ETFs Of The Week Amid Biotech Rebound

    Benzinga
  75. Regeneron Q1 Earnings Beat As Eylea Research Pays Off

    IBD
  76. Crouching Tigers, Hidden Assets - Smead Capital Management

    GuruFocus
  77. Amgen's Decline Could Be A Good Thing

    Benzinga
  78. Should Amgen's T-Vec Results Be Questioned?

    Benzinga
  79. Amgen drug misses fast track

    IBD
  80. Why Baird Is Upgrading DaVita Healthcare

    Benzinga
  81. Biotechs Weigh On Nasdaq, But Apple, Twitter Hold Firm

    IBD
  82. Amgen Reports An Upbeat Q1 Earnings

    GuruFocus
  83. Stocks Strengthen; Tesla Motors Rises On Battery News

    IBD
  84. Stocks Mildly Higher; China Nods To Visa, MasterCard

    IBD
  85. Amgen, Illumina Crush Views

    IBD
  86. Amgen, Illumina Earnings Hot, Intuitive Surgical Not

    IBD
  87. Amgen Tops Q1 Expectations, Shares Gain

    Benzinga
  88. Strategist: Amgen To Move 3% On Q1 Earnings News

    Benzinga
  89. What The Street...And The Crowd Are Watching At Amgen Before ...

    Benzinga
  90. Amgen Inc.'s First Quarter Earnings Preview - What Could Be In ...

    GuruFocus
  91. 5 Biotech Earnings Under The Microscope This Week

    Benzinga
  92. Amgen's First Drug For Cardiovascular Disease Gets The Green ...

    GuruFocus
  93. Why Amgen Might Start To Turn Around

    Benzinga
  94. Amgen Has A Big Launch Coming Up

    Benzinga
  95. AMGEN

    IBD
  96. AbbVie Upgraded On $7.8 Billion Imbruvica Potential

    IBD
  97. Short Sellers Come Back To Biotech Stocks

    Benzinga
  98. Making Money With Charles Payne: 02/25/15

    FoxBusiness
  99. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  100. A Look At Dan Loeb's Diversified 13F

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!